SARS-CoV-2感染后接受加强mRNA疫苗接种的慢性淋巴细胞白血病免疫功能低下患者的混合免疫。 - Suppr

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.

作者信息

Blixt Lisa, Gao Yu, Wullimann David, Murén Ingelman-Sundberg Hanna, Muschiol Sandra, Healy Katie, Bogdanovic Gordana, Pin Elisa, Nilsson Peter, Kjellander Christian, Grifoni Alba, Sette Alessandro, Sällberg Chen Margaret, Ljunggren Hans-Gustaf, Buggert Marcus, Hansson Lotta, Österborg Anders

机构信息

Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

出版信息

Blood. 2022 Dec 1;140(22):2403-2407. doi: 10.1182/blood.2022016815.

DOI:10.1182/blood.2022016815

PMID:36150168

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9512527/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05de/9837432/81a4a6905d3a/BLOOD_BLD-2022-016815-gr1.jpg

相似文献

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.

Blood. 2022 Dec 1;140(22):2403-2407. doi: 10.1182/blood.2022016815.

Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.

Eur J Haematol. 2024 May;112(5):788-793. doi: 10.1111/ejh.14170. Epub 2024 Feb 4.

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.

Int J Cancer. 2023 Feb 15;152(4):705-712. doi: 10.1002/ijc.34209. Epub 2022 Jul 27.

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.

Haematologica. 2022 Apr 1;107(4):1000-1003. doi: 10.3324/haematol.2021.280300.

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.

EBioMedicine. 2021 Dec;74:103705. doi: 10.1016/j.ebiom.2021.103705. Epub 2021 Nov 30.

Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.

Eur J Haematol. 2022 Feb;108(2):91-98. doi: 10.1111/ejh.13722. Epub 2021 Dec 5.

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.

Blood Adv. 2022 Jan 11;6(1):148-151. doi: 10.1182/bloodadvances.2021005998.

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.

Chemotherapy. 2022;67(2):91-95. doi: 10.1159/000521229. Epub 2021 Dec 6.

Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.

Hematol Oncol. 2022 Aug;40(3):313-319. doi: 10.1002/hon.2990. Epub 2022 Mar 23.

SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.

Haematologica. 2022 Oct 1;107(10):2480-2484. doi: 10.3324/haematol.2022.280982.

引用本文的文献

The immunological impact of revaccination in a hybrid-immune world.

Front Immunol. 2025 Jun 9;16:1588259. doi: 10.3389/fimmu.2025.1588259. eCollection 2025.

Uptake of the first to fifth doses of coronavirus disease 2019 vaccine in individuals with chronic lymphocytic leukaemia: A nationwide cohort study in Sweden.

EJHaem. 2025 Jan 6;6(1):e1077. doi: 10.1002/jha2.1077. eCollection 2025 Feb.

COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.

Cell Commun Signal. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9.

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

J Hematol. 2023 Aug;12(4):170-175. doi: 10.14740/jh1140. Epub 2023 Aug 8.

BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients.

Viruses. 2023 Jul 30;15(8):1659. doi: 10.3390/v15081659.

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.

Front Oncol. 2023 Jun 22;13:1212752. doi: 10.3389/fonc.2023.1212752. eCollection 2023.

Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.

本文引用的文献

COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia.

Cancer Cell. 2022 Jun 13;40(6):584-586. doi: 10.1016/j.ccell.2022.05.001. Epub 2022 May 6.

Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.

Lancet Infect Dis. 2022 Jun;22(6):781-790. doi: 10.1016/S1473-3099(22)00143-8. Epub 2022 Apr 1.

Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.

Lancet Infect Dis. 2022 Jun;22(6):791-801. doi: 10.1016/S1473-3099(22)00140-2. Epub 2022 Apr 1.

Cellular Immunity-The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination.

Vaccines (Basel). 2022 Mar 14;10(3):442. doi: 10.3390/vaccines10030442.

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.

EBioMedicine. 2022 Apr;78:103938. doi: 10.1016/j.ebiom.2022.103938. Epub 2022 Mar 16.

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.

N Engl J Med. 2022 Apr 7;386(14):1377-1380. doi: 10.1056/NEJMc2202542. Epub 2022 Mar 16.

Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.

JAMA Neurol. 2022 Apr 1;79(4):399-404. doi: 10.1001/jamaneurol.2022.0245.

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.

N Engl J Med. 2022 Mar 31;386(13):1207-1220. doi: 10.1056/NEJMoa2118691. Epub 2022 Feb 16.

The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.

Br J Haematol. 2022 May;197(3):306-309. doi: 10.1111/bjh.18088. Epub 2022 Feb 18.

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.

Med. 2022 Feb 11;3(2):137-153.e3. doi: 10.1016/j.medj.2022.01.001. Epub 2022 Jan 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献